Gyre Therapeutics completed its acquisition of Cullgen in an all-stock deal valued at about $300 million, creating a fully integrated biopharmaceutical company with operations in the U.S. and China. The combined company now has a commercial product, ETUARY®, for lung fibrosis in China, and a robust pipeline including F351 for liver fibrosis and targeted protein degraders from Cullgen. This strategic move strengthens Gyre's leadership and innovation capabilities, supporting future global growth and expanding treatment options for fibrosis and inflammatory diseases. The company is advancing multiple late-stage clinical trials and exploring international development opportunities for its key drug candidates.
Confo Therapeutics announced encouraging preclinical data for CFTX-2034, a novel antibody targeting post-bariatric hypoglycemia (PBH), a condition with no approved treatments. The data showed CFTX-2034 effectively controls insulin and GLP-1 secretion...
Pardee Resources Company announced an agreement to sell about 2,465 acres of surface and mineral property in West Virginia for approximately $57 million, priced at $23,000 per acre. The sale depends on certain contingencies and normal closing conditi...
Western Digital's stock surged to a new 52-week high following a bullish upgrade by Morgan Stanley analyst Erik Woodring, who raised his price target from $488 to $650. The optimism is driven by expected 30%+ year-over-year growth in nearline enterpr...
Nuvei announced it will acquire Payoneer in an all-cash deal valued at $2.75 billion, offering Payoneer shareholders $7.40 per share. The merger aims to create a global commerce platform supporting businesses in over 190 countries, enhancing payment ...
Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
